OPEN MARKET SALE AGREEMENT1Open Market Sale Agreement • October 31st, 2024 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $300,000,000 on the terms set forth in this agreement (this “Agreement”).
